Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
Other Sizes |
|
ln Vitro |
Teprenone is an inducer of HSP. Teprenone (geranylgeranyl acetone, 1 μM) effectively inhibits ethanol-induced exfoliation and lowers lactate dehydrogenase (LDH) release from stomach mucosal cells. Teprenone (1 μM) steadily elevates HSC70 levels and rapidly accumulates stress-induced concentrations of HSP90, HSP70, and HSP60 within 30-60 minutes. Teprenone also activates heat shock factor 1[1]. Teprenone (0-20 μM) modestly enhances the viability of human umbilical vein endothelial cells (HUVEC) after irradiation (IR). Teprenone (10 μM) showed no effect on HUVEC migration and invasion but increased HUVEC tube formation and wound healing with or without IR. Teprenone (10 μM) also increases angiogenesis by increasing VEGF and eNOS production in HUVEC [3].
|
---|---|
ln Vivo |
In comparison to rats given with a vehicle, rats treated with teprenone (200 mg/kg, p.o.) exhibit increased stress in their mucosa and an accumulation of HSP70 mRNA. Improve that accumulation. After a stress load of two and four hours, rats treated with teprenone (200 mg/kg) orally can dramatically reduce the formation of ulcers [1]. Retinal ganglion cells (RGC) in rats treated with 200 mg/kg teprenone on a daily basis express HSP72. Teprenone mitigated optic nerve damage, enhanced HSP72, decreased the amount of TUNEL-positive cells in the RGC layer, and greatly decreased RGC loss (measured following an increase in intraocular pressure, or IOP) in a rat model of glaucoma [2]. Mitigation of radiation-induced intestinal damage in mice can be achieved by teprenone (200 mg/kg, orally)[3].
|
References |
|
Additional Infomation |
Teprenone is a terpene ketone in which a (9E,13E)-geranylgernayl group is bonded to one of the alpha-methyls of acetone (it is a mixture of 5E- and 5Z-geoisomers in a 3:2 ratio). It has a role as an anti-ulcer drug, a cardioprotective agent, a hepatoprotective agent, a nephroprotective agent, a neuroprotective agent and a Hsp70 inducer. It is a methyl ketone and a terpene ketone. It contains a geranylgeranyl group.
Mechanism of Action Teprenone acts as an anti-ulcer and gastric mucoprotective agent used to treat gastric ulcers and gastritis. Currently, the full mechanisms of action are still unclear. |
Molecular Formula |
C23H38O
|
---|---|
Molecular Weight |
330.5472
|
Exact Mass |
330.292
|
CAS # |
6809-52-5
|
Related CAS # |
(5E,9E,13E)-Teprenone;3796-63-2
|
PubChem CID |
5282199
|
Appearance |
Colorless to light yellow liquid
|
Density |
0.9±0.1 g/cm3
|
Boiling Point |
442.2±24.0 °C at 760 mmHg
|
Flash Point |
168.0±9.8 °C
|
Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
Index of Refraction |
1.483
|
LogP |
8.2
|
Hydrogen Bond Donor Count |
0
|
Hydrogen Bond Acceptor Count |
1
|
Rotatable Bond Count |
12
|
Heavy Atom Count |
24
|
Complexity |
482
|
Defined Atom Stereocenter Count |
0
|
SMILES |
O=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H]
|
InChi Key |
HUCXKZBETONXFO-NJFMWZAGSA-N
|
InChi Code |
InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17+
|
Chemical Name |
(5E,9E,13E)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~302.53 mM)
Ethanol : ~50 mg/mL (~151.26 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.56 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: 2.5 mg/mL (7.56 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0253 mL | 15.1263 mL | 30.2526 mL | |
5 mM | 0.6051 mL | 3.0253 mL | 6.0505 mL | |
10 mM | 0.3025 mL | 1.5126 mL | 3.0253 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.